荣昌、石药接连斩获大单背后:中国药企半年吸金近500亿美元,跨国巨头为何疯狂“扫货”|创新药观察

华夏时报
26 Jun

全球医药巨头正将中国实验室变成新药“弹药库”。  近日,荣昌生物宣布将旗下自主研发的产品泰它西普有偿许可给美国纳斯达克上市公司VorBiopharma Inc.(下称“Vor Bio”),Vor Bio将获得泰它西普在除大中华区以外的全球范围内开发、生产和商业化的独家权利;而荣昌生物将获得4500万美元的首付款和价值8000万美元的认股权证,交易未来总金额最高可达42.3亿美元。  无独有偶,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10